{
  "symbol": "APDN",
  "company_name": "Applied Dna Scns",
  "ir_website": "https://investors.adnas.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "See all",
          "url": "https://investors.adnas.com/news-events/press-releases/",
          "content": "[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# Press Releases\n"
        }
      ]
    },
    {
      "section_name": "Company Events",
      "links": [
        {
          "title": "Company Events",
          "url": "https://investors.adnas.com/news-events/company-events/",
          "content": "[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# Company Events\n\nSubtitle:\n\nDisclosure of Results\n\nWebcast\n\nMore than one event\n\nConferences\n\nOther Events\n\n## Future events\n\nDate | Event | Details | Export  \n---|---|---|---  \n  \n## Past events\n\nDate | Event | Details  \n---|---|---\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.adnas.com/sec-filings/",
          "content": "[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# SEC Filings\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "FAQ",
          "url": "https://investors.adnas.com/resources/faq/",
          "content": "[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# FAQ\n\nWhat does Applied DNA Sciences do? \n\nApplied DNA Sciences is a biotechnology company developing and commercializing technologies to produce and detect DNA and RNA. Using PCR to enable the production and detection of DNA and RNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics (including biologics and drugs) and, through our recent acquisition of Spindle Biotech, Inc. (“Spindle”), the development and sale of a proprietary RNA polymerase (“RNAP”) for use in the production of messenger RNA (“mRNA”) therapeutics (“Therapeutic DNA Production Services”); (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services (“MDx Testing Services”); and (iii) the manufacture and detection of DNA for industrial supply chain security services (“DNA Tagging and Security Products and Services”).\n\nOur growth strategy is to primarily focus our resources on the further development, commercialization, and customer adoption of our Therapeutic DNA Production Services, including the expansion of our contract development and manufacturing operation (“CDMO”) for the manufacture of synthetic DNA for use in the production of nucleic acid-based therapies, and to further expand and commercialize our MDx Testing Services through genetic testing.\n\nWhere is the Company headquartered? \n\nThe Applied DNA Sciences Inc. corporate headquarters are located at:\n\n50 Health Sciences Drive Stony Brook, NY 11790 Tel +1-631-240-8800 Fax +1-631-240-8900\n\nWhere is the Company incorporated? \n\nApplied DNA Sciences is a Delaware corporation.\n\nWhat is the Company's fiscal year? \n\nApplied DNA Sciences fiscal year ends September 30.\n\nOn which exchange is the Company's common stock traded? \n\nApplied DNA Sciences common stock is traded on The NASDAQ Capital Market under the ticker symbol APDN.\n\nApplied DNA Sciences warrants are traded on the OTC Markets under the ticker symbol APPDW.\n\nWhat is the Company's current shares outstanding count? \n\nApproximately 50.9 million shares of common stock are outstanding as of November 11, 2024.\n\nWho are the Company's auditors? \n\nMarcum LLP 10 Melville Park Road Melville, NY Tel: 631 414 4000 Fax: 631 414 4001 <http://www.marcumllp.com>\n\nWho is the Company's transfer agent? How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate? \n\nEquiniti Trust Company Tel: [(800) 937-5449](tel:8009375449) OR [(718) 921-8124](tel:7189218124) URL: <https://equiniti.com/us/ast-access/individuals/>\n\nThe transfer agent is responsible for maintaining all records of stockholders (including change of address, telephone number, and name), canceling or issuing stock certificates, and resolving problems related to lost, destroyed, or stolen certificates.\n\nCan I buy stock directly from the Company? \n\nNo, Applied DNA Sciences does not offer a direct stock purchase plan. All purchases of stock must be made in the public market.\n\nDoes the Company pay a dividend? \n\nNo, Applied DNA Sciences does not pay dividends at this time.\n\nHow can I view documents the Company has filed with the Securities and Exchange Commission, including its Forms 10-Qs and 10-Ks? \n\nSEC filings are available at the following address: [SEC Filings](https://otc-ir-adnas.mz-sites.com/sec-filings/)\n\nHow do I contact Investor Relations to obtain more information about the Company? \n\nPlease contact Sanjay M. Hurry Executive Director, Investor Relations and Corporate Communications E: sanjay.hurry@adnas.com M: 917-733-5573\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.adnas.com/resources/email-alerts/",
          "content": "Press Alt+1 for screen-reader mode, Alt+0 to cancel[Accessibility Screen-Reader Guide, Feedback, and Issue Reporting](https://accessibe.com/blog/knowledgebase/screen-reader-guide)\n\n[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# Email Alerts\n\nEmail*\n\nFirst Name\n\nLast Name\n\nCompany\n\nTitle\n\nPhone\n\nInvestor Type Individual Investor Individual Investor, public & private co's Broker-Dealer, Analyst Broker-Dealer, Broker/FC Broker-Dealer, Institutional Sales Broker-Dealer, Investment Banker Broker-Dealer, Trading Broker-Dealer, Other Buy-side, Analyst Buy-side, Portfolio Manager Buy-side, Trading Buy-side, Venture Capitalist Buy-side, Trustee Buy-side, Other Corporate, Franchiser Corporate, IR/PR Corporate, Management Corporate, Treasury/M&A Corporate, Other Media, Editor Media, Journalist Media, Library Media, Other Services, Accounting Services, Consulting Services, IR/PR Services, Legal Services, Other Other, Other\n\nPress Releases\n\nAll SEC Filings\n\n10-K Filings\n\n10-Q Filings\n\n8-K Filings\n\nProxy Statements\n\nSection 16 Filings - End of day\n\nStock Quote - End of Day\n\nUnsubscribe from all email communications.\n"
        },
        {
          "title": "Contact IR",
          "url": "https://investors.adnas.com/resources/contact-ir/",
          "content": "[Skip to main Content](#content)\n\n[ ![Applied DNA Sciences IR](https://investors.adnas.com/wp-content/uploads/sites/775/2021/06/logo.png) ](https://investors.adnas.com \"Link to Applied DNA Sciences IR homepage\")\n\n[Go to Corporate Home Page](https://adnas.com/ \"Link to Go to Corporate Home Page\")\n\n# Contact IR\n\nEmail successfully sent!\n\nemail Name* Email* Phone* Company Message*\n\nI have read and accept the [Privacy Policy](/privacy-policy/) and [Terms and Conditions of Use](/terms-conditions/).\n\nFill the Captcha  Send\n\n### Contact\n\nSanjay M. Hurry Executive Director, Investor Relations and Corporate Communications sanjay.hurry@adnas.com M: 917-733-5573\n"
        }
      ]
    }
  ]
}